Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
4 Apr 24
6-K
Current report (foreign)
19 Mar 24
6-K
Current report (foreign)
15 Mar 24
EFFECT
Notice of effectiveness
30 Nov 23
POS AM
Prospectus update (post-effective amendment)
22 Nov 23
6-K
Current report (foreign)
22 Nov 23
6-K
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
20 Nov 23
POS AM
Prospectus update (post-effective amendment)
1 Nov 23
6-K
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
26 Sep 23
6-K
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
22 Sep 23
6-K/A
Current report (foreign) (amended)
21 Sep 23
6-K
Current report (foreign)
20 Sep 23
6-K
Current report (foreign)
13 Sep 23
6-K
Current report (foreign)
9 Aug 23
6-K
Current report (foreign)
9 Aug 23
6-K
Consolidated Financial Statements
2 Aug 23
6-K
Current report (foreign)
18 Jul 23
424B4
Prospectus supplement with pricing info
18 Jul 23
EFFECT
Notice of effectiveness
17 Jul 23
6-K
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
14 Jul 23
F-1/A
Registration statement (foreign) (amended)
13 Jul 23
CORRESP
Correspondence with SEC
12 Jul 23
CORRESP
Correspondence with SEC
12 Jul 23
F-1/A
Registration statement (foreign) (amended)
12 Jul 23
6-K
Current report (foreign)
10 Jul 23
FWP
Free writing prospectus
28 Jun 23
F-1/A
Registration statement (foreign) (amended)
28 Jun 23
F-1
Registration statement (foreign)
16 Jun 23
6-K
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results
1 Jun 23
6-K
Current report (foreign)
12 May 23
6-K
Current report (foreign)
11 May 23
6-K
Current report (foreign)
9 May 23
6-K
Current report (foreign)
4 May 23
6-K
Galmed Pharmaceuticals forms a Strategic Partnership
4 May 23
6-K
Current report (foreign)
30 Mar 23
20-F
2022 FY
Annual report (foreign)
29 Mar 23
6-K
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
8 Feb 23
6-K
Current report (foreign)
5 Jan 23
6-K
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
4 Jan 23
6-K
Current report (foreign)
14 Dec 22
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Baharaff Allen
12 Feb 24
SC 13G
CVI Investments, Inc.
21 Jul 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
Baharaff Allen
7 Feb 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 22
SC 13G/A
Baharaff Allen
11 Feb 22
SC 13G/A
Ibex Investors LLC
27 Jan 22
SC 13G
Nantahala Capital Management, LLC
16 Feb 21
SC 13G/A
Baharaff Allen
12 Feb 21
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
12 Feb 21
SC 13G/A
Ibex Investors LLC
15 Jan 21
SC 13G
Ibex Investors LLC
28 Jul 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Galmed Pharmaceuticals Ltd.
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G/A
Galmed Pharmaceuticals Ltd.
14 Feb 19
SC 13G/A
Galmed Pharmaceuticals Ltd.
14 Feb 19
SC 13G/A
Galmed Pharmaceuticals Ltd.
11 Feb 19
SC 13G/A
Galmed Pharmaceuticals Ltd.
22 Jun 18
SC 13G
Galmed Pharmaceuticals Ltd.
16 Apr 18
SC 13G/A
Galmed Pharmaceuticals Ltd.
26 Jan 18
SC 13G/A
Galmed Pharmaceuticals Ltd.
26 Jan 18
SC 13G
Galmed Pharmaceuticals Ltd.
18 Dec 17
SC 13G/A
Galmed Pharmaceuticals Ltd.
13 Feb 17
SC 13G/A
Galmed Pharmaceuticals Ltd.
13 Feb 17
SC 13G/A
Galmed Pharmaceuticals Ltd.
16 Feb 16
SC 13G
Galmed Pharmaceuticals Ltd.
13 Jan 15
SC 13G
Galmed Pharmaceuticals Ltd.
13 Jan 15